Liver transplantation cases
| Study | Type of cancer | Before/after | Allograft outcome | Checkpoint inhibitor | Year from tx to ICI | IS regimen | Cancer response | Interval between IS reduction and ICI initiation | ICI to rejection time |
|---|---|---|---|---|---|---|---|---|---|
| Tsung et al. (2021) [24] | cSCC | After | No rejection | Cemiplimab×2 | NA | Tac 1 mg | PD | NA | |
| cSCC | After | No rejection | Cemiplimab×12 | NA | Tac 0.5 mg | NA | NA | ||
| Qiu et al. (2020) [55] | HCC Rec | After | No rejection | Camrelizumab | 4 | Tac → sirolimus | PR | 2 yr | |
| Zhuang et al. (2020) [56] | HCC Rec | After | No rejection | Nivolumab | 2.7 | Tac | SD | NA | |
| Biondani et al. (2018) [57] | LUSC | After | No rejection | Nivolumab | 13 | Tac+MMF+Pred → Tac+everolimus+Pred | SD | 4 yr | |
| DeLeon et al. (2018) [58] | HCC Rec | After | No rejection | Nivolumab×3 | 2.7 | Tac | PD | NA | |
| Melanoma | After | No rejection | Pembrolizumab×2 | 5.5 | Everolimus, MMF | CR | NA | ||
| HCC Rec | After | No rejection | Nivolumab×4 | 7.8 | Sirolimus, MMF | PD | NA | ||
| HCC Rec | After | No rejection | Nivolumab×5 | 3.7 | Tac | PD | NA | ||
| HCC Rec | After | No rejection | Nivolumab×2 | 1.2 | Tac | NA | NA | ||
| Melanoma | After | Acute rejection | Nivolumab×2 | 1.1 | Sirolimus | NA | NA | 27 day | |
| HCC Rec | After | Acute rejection | Pembrolizumab×2 | 3.1 | MMF, Pred | NA | NA | 21 day | |
| Gassmann et al. (2018) [59] | HCC | After | Cellular rejection | Nivolumab | 3 | Everolimus | PD | None | 7 day |
| Kuo et al. (2018) [60] | Melanoma | After | No rejection | Ipilimumab then pembrolizumab | 5 | Tac+MMF+Pred → sirolimus+MMF | PR | 1 yr | |
| Rammohan et al. (2018) [61] | HCC | After | No rejection | Pembrolizumab | 3 | Tac/sirolimus | CR | NA | |
| De Toni et al. (2017) [62] | HCC Rec | After | No rejection | Nivolumab×15 | 1 | Tac | SD | NA | |
| Friend et al. (2017) [63] | HCC Rec | After | Cellular rejection | Nivolumab | 4 | Sirolimus 2 mg | NA | NA | 17 day |
| HCC Rec | After | Cellular rejection | Nivolumab | 3 | Tac 4 mg | NA | NA | 7 day | |
| Schvartsman et al. (2017) [64] | Melanoma | After | No rejection | Pembrolizumab | 20 | Tac | CR | NA | |
| Varkaris et al. (2017) [65] | HCC Rec | After | No rejection | Pembrolizumab | 8 | Tac → 50% reduction dose | PD | NA | |
| Morales et al. (2015) [66] | Melanoma | After | No rejection | Ipilimumab×4 | 8 | Sirolimus 3 mg → 1 mg, MMF → off | PR | 3 mo | |
| Ranganath et al. (2015) [67] | Melanoma | After | No rejection | Ipilimumab | 8 | Tac | SD | NA | |
| Chen et al. (2021) [68] | HCC | Before | Acute rejection | Toripalimab×10 | Tac, methylprednisolone | PD | None | 10 hr | |
| Dehghan et al. (2021) [69] | HCC | Before | Acute rejection | Nivolumab | Tac, MMF, Pred | Near CR | None | POD 10 | |
| Qiao et al. (2021) [70] | HCC | Before | Rejection in 1/7 | Pembrolizumab or camrelizumab | Tac, MMF, methylprednisolone, Pred, etc. | PR in 71% | None | POD 12 in one case | |
| Tabrizian et al. (2021) [71] | HCC | Before | Rejection in 1/9 (mild, low Tac level) | Nivolumab | Tac, MMF, Pred | Near CR in 3/9 | None | NA | |
| Nordness et al. (2020) [72] | HCC | Before | Acute rejection | Nivolumab | Tac, MMF, Pred | CR | None | POD 5 | |
| Schwacha-Eipper et al. (2020) [73] | HCC | Before | No rejection | Nivolumab | NA | PR | None |
tx, transplantation; ICI, immune checkpoint inhibitor; IS, immunosuppressant; cSCC, cutaneous squamous cell carcinoma; NA, not applicable; Tac, tacrolimus; PD, progressive disease; HCC, hepatocellular carcinoma recurrence; Rec, recurrence; PR, partial response; SD, stable disease; LUSC, lung squamous cell carcinoma; MMF, mycophenolate mofetil; Pred, prednisone; CR, complete response; POD, postoperative day.